Previous 10 | Next 10 |
Gainers: Jasper Therapeutics (NASDAQ:JSPR) +22%, 23andMe (NASDAQ:ME) +21%, DBV Technologies (NASDAQ:DBVT) +10%, ABVC BioPharma (NASDAQ:ABVC) +10%, Sonoma Pharmaceuticals (NASDAQ:SNOA) +8% Losers: Grove (NASDAQ:GRVI) -12%, Myomo (NYSE:MYO) -11%...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced it has entered into agreements w...
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5 th - 8 th , 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Fall Harvest - Best...
BOSTON, MA / ACCESSWIRE / September 28, 2021 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myom...
Myomo Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro product line, which is steadily gaining traction with rising year-over-year sal...
Patents Expected to be Licensed to Newly Established Joint Venture Company in China Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from n...
Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s...
2Q:22 Results Exceed Our Estimates As Revenue Triples Myomo (NYSE American: MYO) was featured in a company-sponsored research earnings release note published by Sidoti & Company, LLC. The report reads, “There are now more 898 units waiting for reimbursement approval, compare...
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +84%, Allied Healthcare Products (NASDAQ:AHPI) +39%, IMV (NASDAQ:IMV) +29%, Exagen (NASDAQ:XGN) +26%, Myomo (NYSE:MYO) +22%. Losers: SmileDirectClub (NASDAQ:SDC) -23%, EyeGate Pharmaceutica...
Myomo, Inc. (MYO) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Kim Golodetz – LHA Investor Relations Paul Gudonis – Chief Executive Officer Dave Henry – Chief Financial Officer Conference Call Participants Scott Henry – ROTH Capit...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 17:00:05 ET Scott Henry from Industrial Alliance Securities issued a price target of $5.75 for MYO on 2024-07-10 15:33:00. The adjusted price target was set to $5.75. At the time of the announcement, MYO was trading at $4.97. The overall price target consensus...
2024-07-10 16:15:02 ET Alliance Global Partners analyst issues BUY recommendation for MYO on July 10, 2024 03:33PM ET. The previous analyst recommendation was Buy. MYO was trading at $4.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-09 10:30:11 ET Lake Street analyst issues BUY recommendation for MYO on July 9, 2024 08:45AM ET. The previous analyst recommendation was Buy. MYO was trading at $4.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...